uploads/2017/12/Chart-008-1.jpg

Allergan on the Street: Analyst Recommendations This December

By

Updated

Wall Street’s estimates

Wall Street analysts estimate that Allergan’s (AGN) top line will rise 10.5% YoY (year-over-year) to $4.27 billion in 4Q17, compared with $3.86 billion in 4Q16.

Analysts also estimate that Allergan’s annual revenues will rise ~9% YoY to ~$15.9 billion in 2017, compared with ~$14.6 billion in 2016. Its EPS (earnings per share) expectation is $16.24 for 2017.

Analysts’ ratings

Allergan’s stock price has fallen ~14.0% the past 12 months and ~21.7% so far in 2017, or YTD (year-to-date). The analysts’ estimates show that the stock has a potential to return ~39.9% over the next 12 months.

The analysts’ recommendations show a 12-month target price of $229.90 per share, compared with its last price of $164.28 per share on December 5, 2017.

Analyst recommendations

As of December 6, 2017, of the 24 analysts tracking Allergan stock, 17 recommend a “buy,” while seven recommend a “hold.” None recommends a “sell.” The consensus rating for Allergan now stands at 2.0, which represents a “strong buy” for momentum and long-term investors.

Remember, changes in analysts’ recommendations are based on changes in the stock’s price, the performance of the company, and positive developments.

Notably, the iShares Core S&P 500 ETF (IVV) has 14.0% of its total assets in Healthcare companies. IVV has 0.2% in Allergan (AGN), 1.0% in Pfizer (PFE), 0.7% in Merck (MRK), and 0.6% in Amgen (AMGN).

More From Market Realist